Meet the founder of startup Volumetric - 3D-bioprinters that print human tissue

 Meet the founder of startup Volumetric - 3D-bioprinters that print human tissue

Our club is pleased to present to you a new startup Volumetric (Houston, Texas) - the production of biomaterials and biotechnologies with living cells using high-speed 3D bioprinting vascular network, which serves as the basis and framework for human tissues.

Startup technology allows you to generate complex biological structures, such as blood vessels and lung alveoli, hundreds of times faster than existing bioprinting technologies, offering more physiologically appropriate tissue models for drug screening and a way to replace donor organs.

Join up meet the founder

The scalability of existing bio-production was limited by printing speed, as long-term biotechnology processes degrade the functionality of tissue cells. Volumetric printing technology is changing the existing paradigm of creating living tissue at a faster rate of speed,as it allows you to create whole objects at once, and not by sequentially adding the main building blocks.  Skin, blood vessels, cartilages, bones and even vital organs as a whole - all this can be done with high resolution, throughput efficiency and accuracy with Volumetric technology.


World trends indicate that during the next 10 years, transplantation of artificially created organs to humans will be possible.

At the moment, the startup has solved the issue of printing the vascular network, which serves as the basis and framework for human tissues and for circulatory systems. Micro organs are created on the basis of the vascular network. Biomaterial for printing is taken from small samples of the patient’s cells directly during an emergency operation and without searching for donors.


The global 3D bioprinting market size was valued at USD 1.2 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 17.4% from 2020 to 2027.  The growth of this market is attributed to a limited number of organ donors, and an increasingly aging population with chronic respiratory diseases.


  • Invested $ 1.8M in 5 rounds;

  • The last round of investing is May 26, 2020;

  • Key investors: Methuselah Foundation (Founding Investors), Methuselah Fund, TMC Venture Fund, SandHill Angels, Y Combinator, Social Starts, Joyance Partners, Liquid 2 Ventures, Social Starts, Joyance Partners, Kingsley Advani.


  • 3D printers use proprietary bioinks;

  • Materials, process, and compositions are patent-pending;

  • Distributed and sold worldwide by a distributor of CELLINK AB;

  • Sold 120 printers since Summer 2019.


Setting up developmental contracts with top 20 pharma for initial validation studies:

  • Duration 18 months;

  • $ 1 - $ 1,5M each;

  • Opportunities over $ 20M.


  • Founded in 2018;

  • Revenue up to date 2019 $ 1.5M;

  • 2 trademarks registered;

  • Assembly, quality assurance done in-house in 5,000 sq ft facility in Houston


  Join up meet the founder
Date of publication: 14.07.2020

You need to login

0 voices
Sign in/Sign up
I like the news
Do not like